Walleye Capital
JAZZ icon

Walleye Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Walleye Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$454K Sell
2,400
-900
-27% -$157K ﹤0.01% 2745
2025
Q4 		$561K Buy
+3,300
New +$506K ﹤0.01% 2887
2024
Q3 		– Sell
-6,400
Closed -$683K – 5581
2024
Q2 		$683K Sell
6,400
-2,200
-26% -$242K ﹤0.01% 3214
2024
Q1 		$1.04M Buy
8,600
+6,500
+310% +$796K ﹤0.01% 2556
2023
Q4 		$258K Sell
2,100
-600
-22% -$74.9K ﹤0.01% 3485
2023
Q3 		$349K Buy
2,700
+2,200
+440% +$293K ﹤0.01% 3106
2023
Q2 		$62K Buy
+500
New +$67.3K ﹤0.01% 3586
2023
Q1 		– Sell
-1,800
Closed -$287K – 4154
2022
Q4 		$287K Sell
1,800
-3,500
-66% -$513K 0.01% 1823
2022
Q3 		$706K Buy
+5,300
New +$806K 0.01% 1203
2020
Q1 		– Sell
-7,600
Closed -$1.14M – 1301
2019
Q4 		$1.14M Sell
7,600
-10,600
-58% -$1.44M 0.07% 368
2019
Q3 		$2.33M Buy
18,200
+15,300
+528% +$2.05M 0.14% 188
2019
Q2 		$413K Sell
2,900
-10,300
-78% -$1.38M 0.05% 580
2019
Q1 		$1.89M Buy
+13,200
New +$1.72M 0.31% 50

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Walleye Capital's JAZZ Position: Q1 2026 in Review

Walleye Capital reduced its Jazz Pharmaceuticals (JAZZ) stake by 25% in Q1 2026, selling an estimated $4.96M and leaving 87,365 shares worth $16.5M. The position accounts for 0.07% of the portfolio, ranked #244.

Walleye Capital first reported a position in JAZZ in Q1 2019 and has held it in 15 quarters since. The position peaked at $19.7M in Q4 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Walleye Capital held 87,365 shares of Jazz Pharmaceuticals worth $16.5M as of Q1 2026.
  • Walleye Capital sold 28,393 Jazz Pharmaceuticals shares in Q1 2026, an estimated $4.96M.
  • Jazz Pharmaceuticals made up 0.07% of Walleye Capital's portfolio in Q1 2026, its #244 holding.
  • Walleye Capital first reported a position in Jazz Pharmaceuticals in Q1 2019 and has held it in 15 quarters since.
  • Walleye Capital's Jazz Pharmaceuticals position peaked at $19.7M in Q4 2025.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.